AIM ImmunoTech Inc.
AIMAIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
Drugs in Pipeline
5
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Ampligen
Chronic Fatigue Syndrome
Alferon LDO
Severe Acute Respiratory Syndrome
Rintatolimod
Post COVID-19 Condition
poly I-poly C12U
HIV Seropositivity
AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide
Asthma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ampligen | Phase 3 | Chronic Fatigue Syndrome | - | - |
Alferon LDO | Phase 2 | Severe Acute Respiratory Syndrome | - | - |
Rintatolimod | Phase 2 | Post COVID-19 Condition | - | - |
poly I-poly C12U | Phase 2 | HIV Seropositivity | - | - |
AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide | Phase 2 | Asthma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in AIM ImmunoTech Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in AIM ImmunoTech Inc.'s (AIM) pipeline across Phase 3, Phase 2. Its lead program is Ampligen (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is AIM ImmunoTech Inc.'s next FDA catalyst?→
AIM ImmunoTech Inc.'s (AIM) next tracked catalyst is a Earnings expected November 16, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AIM biotech catalysts?→
Add AIM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow AIM ImmunoTech Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.